Eli Lilly shares see a dip — What is pressuring the stock

Traders Union
All News
Financial News
Eli lilly slides 2.40% today

Highlights

Eli Lilly will invest $3 billion over ten years to expand manufacturing and supply for its new oral GLP-1 diabetes and obesity drug in China.
The company advanced its obesity portfolio by submitting orforglipron for approval in China and expanding U.S. access to Zepbound despite broader selling pressure.
Shares remain under short-term downside momentum below key averages, but weekly indicators favor a probable rebound toward the $993–$1,018 range.

China investment and U.S. access moves fail to offset selling pressure

Eli Lilly announced a commitment to invest $3 billion in China over the next decade to expand its manufacturing capacity and supply chain, supporting the production of a new oral GLP-1 drug aimed at diabetes and obesity treatments. The company also submitted a marketing application in China for its experimental weight-loss drug, orforglipron. In addition, Eli Lilly has launched Employer Connect to improve access to its obesity medication Zepbound for U.S. workers and issued an open letter highlighting potential safety risks related to compounded tirzepatide combined with vitamin B12, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, believes Eli Lilly remains under significant short- and medium-term selling pressure. He notes that LLY's failure to hold above the SMA-20 and SMA-50, combined with neutral momentum on the AO and weak trend signals, raises doubts about immediate recovery. Kharitonov is critical of the reliance on long-term support, warning that oversold technicals do not guarantee a near-term rebound. He draws attention to market indifference toward recent positive corporate news, emphasizing persistent selling despite new investments and drug launches. "For me, a break below $975 could accelerate downside — caution is justified until the market proves otherwise."

Viktoras Karapetjanc, expert at Traders Union, sees robust growth potential for Eli Lilly as the company invests $3 billion in China and expands access to its leading obesity therapies. He highlights that the bullish structure remains intact with LLY well above the SMA-200 and strong institutional momentum backing long-term expansion. Karapetjanc views new product launches and global supply chain investments as major catalysts for further demand. He expects the coming week to offer multiple setups for bulls if the price reclaims ground above $1,039.80. "I remain confident that Eli Lilly's growth story is just gaining traction — further upside is expected as global fundamentals strengthen."

Parshwa Turakhiya, analyst, notes that LLY’s recent slide creates short-term opportunities shaped by oversold signals on daily and intraday charts. He sees sentiment subdued for now despite positive headlines around new investments and obesity drug launches. Turakhiya suggests strategies to capitalize on an anticipated sideways range between $993.49 and $1,018.36, favoring scenario-driven setups. "Traders should watch for a quick reversal above $1,039.80 or be ready for renewed weakness if $975 fails — sentiment will shift fast."

Technical momentum weakened as oversold signals meet support at SMA-200

LLY is trading at $975.84, notably below both the SMA-20 ($1,019.95) and SMA-50 ($1,042.78), but well above the SMA-200 ($885.01). This configuration points to persistent short- and medium-term selling pressure, though longer-term structure remains bullish with major support from the SMA-200. The nearest dynamic resistance is the Ichimoku Kijun at $1,039.80, with longer-term support beginning near $885.01. Momentum readings on the daily timeframe show limited upside with MACD signaling a sell and ADX indicating a weak trend. Both daily and intraday RSI, CCI, and BBP point toward oversold conditions and persistent selling dominance, while Stoch RSI fluctuates between neutral and oversold across timeframes. AO is neutral but does not counter the established downward momentum.

Last time, analysts noted that Eli Lilly traded just below its short-term moving average but remained well above key medium- and long-term supports, with mixed momentum signals showing bullish medium-term MACD, moderate ADX trend, and some oversold short-term readings. Technical outlook highlights a rangebound bias between identified support and resistance levels, with a 75% probability of upside breakout if buying returns, underpinned by positive sentiment from pipeline developments and institutional interest.

Source of Data: LLY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.